慢性肺病患者中的 COVID-19 。
COVID-19 in Patients with Chronic Lung Disease.
机构信息
University of Nottingham, Medical School, Nottingham NG7 2UH, United Kingdom.
National Heart and Lung Institute, Imperial College London, Guy Scadding Building, Cale Street, London SW3 6LY, United Kingdom.
出版信息
Clin Chest Med. 2023 Jun;44(2):385-393. doi: 10.1016/j.ccm.2022.11.013. Epub 2022 Nov 22.
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that causes an acute respiratory tract infection known as coronavirus disease 2019 (COVID-19). SARS-CoV-2 enters cells by binding the ACE2 receptor and coreceptors notably TMPRSS2 or Cathepsin L. Severe COVID-19 infection can lead to acute lung injury. Below we describe the current evidence of the impact of common chronic lung diseases (CLDs) on the development of COVID-19. The impact of treatment of CLD on COVID-19 and any risk of vaccination in patients with CLD are considered.
摘要
严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）是一种新型冠状病毒，可引起急性呼吸道感染，称为 2019 年冠状病毒病（COVID-19）。SARS-CoV-2 通过结合 ACE2 受体和辅助受体（特别是 TMPRSS2 或组织蛋白酶 L）进入细胞。严重的 COVID-19 感染可导致急性肺损伤。下面我们描述了常见慢性肺部疾病（CLD）对 COVID-19 发展的影响的现有证据。还考虑了 CLD 治疗对 COVID-19 的影响以及 CLD 患者接种疫苗的任何风险。
相似文献
1
COVID-19 in Patients with Chronic Lung Disease.慢性肺病患者中的 COVID-19 。
Clin Chest Med. 2023 Jun;44(2):385-393. doi: 10.1016/j.ccm.2022.11.013. Epub 2022 Nov 22.
2
Single-cell analysis of SARS-CoV-2 receptor ACE2 and spike protein priming expression of proteases in the human heart.单细胞分析 SARS-CoV-2 受体 ACE2 和刺突蛋白在人心脏中对蛋白酶的预激活表达。
Cardiovasc Res. 2020 Aug 1;116(10):1733-1741. doi: 10.1093/cvr/cvaa191.
3
Pathophysiological conditions induced by SARS-CoV-2 infection reduce ACE2 expression in the lung.SARS-CoV-2 感染引起的病理生理状况会降低肺部的 ACE2 表达。
Front Immunol. 2022 Nov 4;13:1028613. doi: 10.3389/fimmu.2022.1028613. eCollection 2022.
4
COVID-19 Severity and Mortality in Veterans with Chronic Lung Disease.慢性肺部疾病退伍军人的 COVID-19 严重程度和死亡率。
Ann Am Thorac Soc. 2024 Jul;21(7):1034-1043. doi: 10.1513/AnnalsATS.202311-974OC.
5
Apalutamide Prevents SARS-CoV-2 Infection in Lung Epithelial Cells and in Human Nasal Epithelial Cells.阿帕鲁胺可预防肺上皮细胞和人鼻腔上皮细胞中的 SARS-CoV-2 感染。
Int J Mol Sci. 2023 Feb 7;24(4):3288. doi: 10.3390/ijms24043288.
6
Comprehensive analysis of two potential novel SARS-CoV-2 entries, TMPRSS2 and IFITM3, in healthy individuals and cancer patients.综合分析健康个体和癌症患者中两种潜在的新型 SARS-CoV-2 进入受体 TMPRSS2 和 IFITM3。
Int J Biol Sci. 2020 Sep 30;16(15):3028-3036. doi: 10.7150/ijbs.51234. eCollection 2020.
7
Type 2 inflammation modulates ACE2 and TMPRSS2 in airway epithelial cells.2 型炎症调节气道上皮细胞中的 ACE2 和 TMPRSS2。
J Allergy Clin Immunol. 2020 Jul;146(1):80-88.e8. doi: 10.1016/j.jaci.2020.05.004. Epub 2020 May 15.
8
Disequilibrium between the classic renin-angiotensin system and its opposing arm in SARS-CoV-2-related lung injury.新型冠状病毒相关肺损伤中经典肾素-血管紧张素系统与其拮抗系统之间的失衡。
Am J Physiol Lung Cell Mol Physiol. 2020 Aug 1;319(2):L325-L336. doi: 10.1152/ajplung.00189.2020. Epub 2020 Jul 8.
9
Lung Cancer Models Reveal Severe Acute Respiratory Syndrome Coronavirus 2-Induced Epithelial-to-Mesenchymal Transition Contributes to Coronavirus Disease 2019 Pathophysiology.肺癌模型揭示严重急性呼吸综合征冠状病毒 2 诱导的上皮间质转化导致 2019 年冠状病毒病发病机制。
J Thorac Oncol. 2021 Nov;16(11):1821-1839. doi: 10.1016/j.jtho.2021.07.002. Epub 2021 Jul 16.
10
ACE2 (Angiotensin-Converting Enzyme 2) in Cardiopulmonary Diseases: Ramifications for the Control of SARS-CoV-2.心肺疾病中的 ACE2（血管紧张素转换酶 2）：对 SARS-CoV-2 控制的影响。
Hypertension. 2020 Sep;76(3):651-661. doi: 10.1161/HYPERTENSIONAHA.120.15595. Epub 2020 Aug 12.
引用本文的文献
1
Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment for COVID-19: "Symptom Rebound".新冠病毒感染使用奈玛特韦-利托那韦（帕罗韦德）治疗后寻求医疗护理的风险因素：“症状反弹”
Viruses. 2025 May 29;17(6):782. doi: 10.3390/v17060782.
2
Demographic and regional trends of sepsis mortality in the United States, 1999-2022.1999 - 2022年美国脓毒症死亡率的人口统计学和区域趋势
BMC Infect Dis. 2025 Apr 11;25(1):504. doi: 10.1186/s12879-025-10921-7.
3
Comparative analysis of COVID-19-related mortality risk in chronic lower respiratory disease and interstitial lung disease.慢性下呼吸道疾病和间质性肺疾病中与 COVID-19 相关的死亡风险的比较分析。
Sarcoidosis Vasc Diffuse Lung Dis. 2024 Dec 10;41(4):e2024057. doi: 10.36141/svdld.v41i4.16139.
4
TAS2R38 Genotype Does Not Affect SARS-CoV-2 Infection in Primary Ciliary Dyskinesia.TAS2R38 基因型不会影响原发性纤毛运动障碍患者中的 SARS-CoV-2 感染。
Int J Mol Sci. 2024 Aug 8;25(16):8635. doi: 10.3390/ijms25168635.
5
Cell-surface d-glucuronyl C5-epimerase binds to porcine deltacoronavirus spike protein facilitating viral entry.细胞表面 d-葡糖醛酸 C5-差向异构酶与猪德尔塔冠状病毒刺突蛋白结合，促进病毒进入。
J Virol. 2024 Aug 20;98(8):e0088024. doi: 10.1128/jvi.00880-24. Epub 2024 Jul 30.
6
Effects of the Novel Coronavirus Pandemic on the Identification and Care of Critically Ill Emergency Patients Not Infected with COVID-19.新型冠状病毒大流行对未感染 COVID-19 的危重症急诊患者识别与救治的影响
Risk Manag Healthc Policy. 2023 Dec 4;16:2661-2672. doi: 10.2147/RMHP.S437690. eCollection 2023.
本文引用的文献
1
COVID-19 mRNA Vaccines and Interstitial Lung Disease Exacerbation: Causation or Just a Temporal Association?新冠病毒mRNA疫苗与间质性肺疾病加重：因果关系还是仅仅是时间上的关联？
Am J Respir Crit Care Med. 2022 Oct 1;206(7):919. doi: 10.1164/rccm.202205-0902LE.
2
Reduced immunogenicity of the mRNA vaccine BNT162b2 in patients with idiopathic pulmonary fibrosis.mRNA疫苗BNT162b2在特发性肺纤维化患者中的免疫原性降低。
ERJ Open Res. 2022 May 3;8(2). doi: 10.1183/23120541.00082-2022. eCollection 2022 Apr.
3
Immunogenicity of the COVID-19 BNT162b2 vaccine in adolescents and young adults with cystic fibrosis.COVID-19 BNT162b2 疫苗在囊性纤维化青少年和年轻成人中的免疫原性。
J Cyst Fibros. 2022 May;21(3):e184-e187. doi: 10.1016/j.jcf.2022.04.004. Epub 2022 Apr 14.
4
COVID-19 Vaccine in Patients with Exacerbation of Idiopathic Pulmonary Fibrosis.特发性肺纤维化急性加重患者的新冠病毒疫苗接种情况
Am J Respir Crit Care Med. 2022 Jul 15;206(2):219-221. doi: 10.1164/rccm.202112-2765LE.
5
Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis.全球、区域和国家 2019 年慢性阻塞性肺疾病（COPD）的患病率、危险因素：系统评价和建模分析。
Lancet Respir Med. 2022 May;10(5):447-458. doi: 10.1016/S2213-2600(21)00511-7. Epub 2022 Mar 10.
6
Different pathogenesis of SARS-CoV-2 Omicron variant in wild-type laboratory mice and hamsters.严重急性呼吸综合征冠状病毒2型奥密克戎变异株在野生型实验小鼠和仓鼠中的不同发病机制。
Signal Transduct Target Ther. 2022 Feb 25;7(1):62. doi: 10.1038/s41392-022-00930-2.
7
Deciphering Respiratory-Virus-Associated Interferon Signaling in COPD Airway Epithelium.解析 COPD 气道上皮中与呼吸道病毒相关的干扰素信号通路。
Medicina (Kaunas). 2022 Jan 13;58(1):121. doi: 10.3390/medicina58010121.
8
Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.新冠病毒疫苗在免疫功能低下人群中的免疫和临床疗效：一项系统评价
Clin Microbiol Infect. 2022 Feb;28(2):163-177. doi: 10.1016/j.cmi.2021.09.036. Epub 2021 Nov 17.
9
The Promoter Polymorphism Associates With Severe COVID-19 in the European Population.启动子多态性与欧洲人群中的重症 COVID-19 相关。
Front Med (Lausanne). 2021 Nov 23;8:668024. doi: 10.3389/fmed.2021.668024. eCollection 2021.
10
Efficacy of Inhaled Ciclesonide for Outpatient Treatment of Adolescents and Adults With Symptomatic COVID-19: A Randomized Clinical Trial.吸入用环索奈德治疗有症状的 COVID-19 青少年和成人患者的门诊疗效：一项随机临床试验。
JAMA Intern Med. 2022 Jan 1;182(1):42-49. doi: 10.1001/jamainternmed.2021.6759.
Zotero 插件